Last reviewed · How we verify

NCT05347706

Protocol for Feeding Intolerance in Preterm Infants

Status unknown NA Last updated 26 April 2022
What this trial tests

NA trial testing formula in Feeding Intolerance in 190 participants. Status unknown.

Timeline
1 March 2021
Primary endpoint
31 May 2024
31 December 2024

Quick facts

Lead sponsorChildren's Hospital of Chongqing Medical University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment190
Start date1 March 2021
Primary completion31 May 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Chongqing Medical University

Who can join

Eligibility, any sex, with Feeding Intolerance or Preterm Infants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Feeding intolerance is a common problem in preterm infants, which is associated with increased risk of infections, prolonged hospitalization, and increased economic costs. When human milk is not available, formula feeding is required. Amino acid-based formula and extensively hydrolyzed formula could be considered to use for severe feeding intolerance. A recent Cochrane meta-analysis found that preterm infants fed extensively hydrolyzed formula compared with standard formula could not reduce the risk of feeding intolerance and necrotizing enterocolitis, and weight gain was slower. Some studies reported that preterm infants fed amino acid-based formula could reduce the gastric residual volume. Investigators hypothesize that amino acid-based formula can improve feeding intolerance and establish full enteral feeding more rapidly in preterm infants compared with extensively hydrolyzed formula. Method: The randomized, prospective, controlled trial is to be conducted in Children's Hospital of Chongqing Medical University (Chongqing, China). A total of 190 preterm infants with gestational age \< 32 weeks or birth weight \< 1500g and with a diagnosis of feeding intolerance will be included. Patients will be randomized to an amino acid-based formula-fed group and an extensively hydrolyzed formula-fed group. The primary outcome is the time (days) to reach full enteral feedings. Secondary outcomes include duration of vomiting and abdominal distension, gastric residual volume, body weight, length and head circumference during hospitalization, length of hospital stay (days), cost of hospitalization, time (days) of parenteral nutrition, change of abdomen circumference, main serum parameters and incidence of adverse events. Discussion: The successful implementation of the study will provide robust evidence for formula alternatives in preterm infants with feeding intolerance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Amino Acid-Based Formula vs. Extensively Hydrolyzed Formula in the Treatment of Feeding Intolerance in Preterm Infants: Study Protocol for a Randomized Controlled Trial.
    Zhong Q, Lu Q, Peng N, Liang XH. · · 2022 · cited 4× · PMID 35711561 · DOI 10.3389/fnut.2022.854121

Verify or expand the search:

Other trials of formula

Trials testing the same drug.

Other recruiting trials for Feeding Intolerance

Currently open trials in the same condition.

Other Children's Hospital of Chongqing Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05347706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing